Written by 
ismagilov/iStock via Getty Images J.P. Morgan has initiated coverage of Septerna (NASDAQ:SEPN) with an overweight rating, citing the company’s platform for GPCR drug design. “Notwithstanding manifold newly actionable GPCR targets, we see Septerna (SEPN) executing a highly attractive pipeline strategy, focused on validated targets Source link
With 2025 on the horizon, investors are sharpening their focus on the year ahead, selecting portfolio additions that aim to bring solid returns. “There is reason to be bullish,” says Jordan Jackson, a JPMorgan strategist covering the markets. He highlights positive trends in inflation and interest rates, noting that consumer spending is likely to respond […]